RecruitingNot ApplicableNCT05346393

HRS-AKI Treatment With TIPS in Patients With Cirrhosis

Hepatorenal Syndrome-acute Kidney Injury (HRS-AKI) Treatment With Transjugular Intrahepatic Portosystemic Shunt in Patients With Cirrhosis. A Randomized Controlled Trial

Sponsor

Jena University Hospital

Enrollment

124 participants

Start Date

Nov 29, 2022

Study Type

INTERVENTIONAL

Conditions

hepatorenal syndrome Acute Kidney Injury Cirrhosis, Liver Ascites Hepatic

Summary

The study compares the effectiveness and safety of TIPS implantation in patients with HRS-AKI (stage1, 2 and 3) and liver cirrhosis with standard therapy (drug therapy with terlipressin + albumin).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Standard of Care and a procedure called TIPS for people with acute kidney injury, ascites hepatic, and other related conditions. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETIPS

A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver

DRUGStandard of Care

Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.

Locations(14)

University Hospital RWTH Aachen

Aachen, Germany

Charité - Universitätsmedizin Berlin CVK

Berlin, Germany

University Hospital Dresden, Medical Clinic I, Gastroenterology

Dresden, Germany

Universitätsklinikum Essen (AöR)

Essen, Germany

University Hospital Freiburg

Freiburg im Breisgau, Germany

University Hospital Halle

Halle, Germany

University Hospital Hamburg-Eppendorf

Hamburg, Germany

Medical University Hannover

Hanover, Germany

Jena University Hospital, Clinic for Inner Medicine IV

Jena, Germany

Klinikum Landshut AdöR der Stadt Landshut

Landshut, Germany

University Hospital Leipzig

Leipzig, Germany

RKH Clinic Ludwigsburg

Ludwigsburg, Germany

Ludwig-Maximilians-University, Klinikum Großhadern

Munich, Germany

University Hospital Münster, Medical Clinic B

Münster, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05346393

Related Trials

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

NCT065359458 locations

Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock?

NCT035474141 location

QOL and Sarcopenia in Patients With Ascites

NCT057267471 location

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

NCT058794329 locations

UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events

NCT058066452 locations